Replies to post #229110 on Biotech Values

[miljenko]

Can anyone tract camostat mesilate (NI-03), who originally developed and who has IP right? So far, it is Japan's Kangen Pharma.

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3606-y

Originally developed as TMPRSS2 inhibitor (as trans-membrane cysteine protease inhibitor), it may show the most efficacious method to combath nCoV pandemic.